Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Experimental Nephrology
Published in: Clinical and Experimental Nephrology 3/2011

01-06-2011 | Case Report

Successful treatment of acute promyelocytic leukemia in a patient on hemodialysis

Authors: Yoshiki Tsuchiya, Yoshifumi Ubara, Tatsuya Suwabe, Junichi Hoshino, Keiichi Sumida, Rikako Hiramatsu, Eiko Hasegawa, Masayuki Yamanouchi, Noriko Hayami, Yuji Marui, Naoki Sawa, Fumi Takemoto, Kenmei Takaichi

Published in: Clinical and Experimental Nephrology | Issue 3/2011

Login to get access

Abstract

Acute promyelocytic leukemia (APL) has the best prognosis among acute leukemias, but there is little data about APL in patients on hemodialysis. A 64-year-old hemodialysis patient was successfully treated for APL by induction therapy with all-trans retinoic acid (ATRA), three courses of consolidation therapy with Ara-C, mitomycin C (MIT), daunorubicin (DNR), and idarubicin (IDR), and maintenance therapy with ATRA. Complete remission has been maintained for 42 months in this patient. With dose modification, ATRA and chemotherapy may be safely given to patients on hemodialysis.
Literature
1.
Menell JS, Cesarman GM, Jacovina AT, McLaughlin MA, Lev EA, Hajjar KA. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med. 1999;340(13):994–1004.CrossRef
2.
Massry SG, Glassock RJ, editors. Textbook of nephrology. Lippincot Williams & Wilkins; 2001.
3.
Rajpurkar M, Alcasabas P, Warrier I, Valentini RP, Fassinger N, Frattarelli DA, et al. Effect of dialysis on all trans retinoic acid levels in a child with acute promyelocytic leukemia and renal failure. Pediatr Blood Cancer. 2007;49(7):994–6.CrossRef
4.
Okazuka K, Masuko M, Seki Y, Hama H, Honma N, Furukawa T, et al. Successful all-trans retinoic acid treatment of acute promyelocytic leukemia in a patient with NPM/RAR fusion. Int J Hematol. 2007;86(3):246–9.CrossRef
5.
Takitani K, Nagai K, Kanbe E, Inoue A, Kawakami C, Kuno T, et al. Pharmacokinetics of all-trans retinoic acid in acute promyelocytic leukemia patients on dialysis. Am J Hematol. 2003;74(2):147–8.CrossRef
6.
Farrington K, Miller P, Varghese Z, Baillod RA, Moorhead JF. Vitamin A toxicity and hypercalcaemia in chronic renal failure. Br Med J (Clin Res Ed). 1981;282(6281):1999–2002.CrossRef
7.
Yamane A, Tsukamoto N, Saitoh T, Uchiumi H, Handa H, Karasawa M, et al. Successful treatment by all-trans retinoic acid in a patient with acute promyelocytic leukemia complicated by liver cirrhosis and polycystic kidney. Intern Med. 2009;48(18):1691–4.CrossRef
8.
Asou N, Kishimoto Y, Kiyoi H, Okada M, Kawai Y, Tsuzuki M, et al. A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood. 2007;110(1):59–66.CrossRef
9.
Takeuchi M, Yamauchi T, Yoshida I, Soda R, Ueda T, Takahashi K. Pharmacokinetics of a standard dose of cytarabine in a patient with acute promyelocytic leukemia undergoing continuous ambulatory peritoneal dialysis. Int J Hematol. 2003;77(2):196–8.CrossRef
10.
D’Incalci M, Rossi C, Zucchetti M, Urso R, Cavalli F, Mangioni C, et al. Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. Cancer Res. 1986;46(5):2566–71.PubMed
11.
Lindner LH, Ostermann H, Hiddemann W, Kiani A, Wurfel M, Illmer T, et al. AraU accumulation in patients with renal insufficiency as a potential mechanism for cytarabine neurotoxicity. Int J Hematol. 2008;88(4):381–6.CrossRef
12.
Au WY, Cheung GT, Yuen TW, Kumana CR, Kwong YL. Successful treatment of relapsed acute promyelocytic leukemia in a patient receiving continuous ambulatory peritoneal dialysis with oral arsenic trioxide. Arch Intern Med. 2005;165(9):1067–8.CrossRef
13.
Yamamoto Y, Sasaki M, Oshimi K, Sugimoto K. Arsenic trioxide in a hemodialytic patient with acute promyelocytic leukemia. Acta Haematol. 2009;122(1):52–3.CrossRef
Metadata
Title
Successful treatment of acute promyelocytic leukemia in a patient on hemodialysis
Authors
Yoshiki Tsuchiya
Yoshifumi Ubara
Tatsuya Suwabe
Junichi Hoshino
Keiichi Sumida
Rikako Hiramatsu
Eiko Hasegawa
Masayuki Yamanouchi
Noriko Hayami
Yuji Marui
Naoki Sawa
Fumi Takemoto
Kenmei Takaichi
Publication date
01-06-2011
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 3/2011
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-011-0405-5

Other articles of this Issue 3/2011

Clinical and Experimental Nephrology 3/2011 Go to the issue

Original Article

Cisplatin induces Sirt1 in association with histone deacetylation and increased Werner syndrome protein in the kidney

Case Report

A case report of retroaortic left renal vein with tumor thrombus of renal cell carcinoma

Case Report

Successful steroid treatment of a patient with autosomal dominant polycystic kidney disease complicated by sarcoidosis

Original Article

Upregulation of calbindin D28k in the late distal tubules in the potassium-loaded adrenalectomized mouse kidney

Case Report

Corticosteroid treatment of kidney disease in a patient with familial lecithin-cholesterol acyltransferase deficiency

Case Report

Nephrotic syndrome developing during induction chemotherapy for childhood acute lymphoblastic leukemia
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits